Global Therapeutic Nuclear Medicines Market Strategic Research Report

Scope of the Report

The global Therapeutic Nuclear Medicines market size is predicted to grow from US$ 4,246 million in 2025 to US$ 8,282 million in 2032; it is expected to grow at a CAGR of 10.1% from 2026 to 2032.

Therapeutic nuclear medicines are a class of pharmaceuticals that utilize radioactive isotopes to deliver cytotoxic radiation directly to diseased tissues, particularly tumors. These agents combine radioisotopes with targeting molecules—such as peptides, antibodies, or small ligands—to emit alpha, beta, or Auger electrons with high precision. This targeted radiation induces cell death while minimizing damage to surrounding healthy tissues. Therapeutic radiopharmaceuticals are especially promising for cancers that are inoperable or unresponsive to conventional therapies, such as prostate cancer and neuroendocrine tumors. With the rapid advances in precision medicine and molecular imaging, this category is emerging as a pivotal frontier in personalized oncology, offering both clinical efficacy and strong commercial potential.

Driven by the advancement of precision medicine, therapeutic nuclear medicines are gaining momentum as a cornerstone of theranostics. Collaborations between major pharmaceutical companies and radioisotope suppliers are accelerating the development of novel radioligands, while regulatory approvals of breakthrough products are expanding the treatment landscape and attracting investor interest. Government policies supporting isotope production, nuclear logistics, and expedited approvals are further unlocking industry potential and enabling faster translation from R&D to clinical practice.

Despite their clinical promise, therapeutic radiopharmaceuticals face considerable industrial barriers. Radioisotope sourcing is restricted due to national strategic controls, and the supply chain is tightly regulated. Manufacturing and distribution require strict compliance with radiation safety, GMP standards, and cold-chain logistics, resulting in high operational thresholds. Additionally, limited awareness among physicians and patients leads to longer adoption cycles, making education and commercialization efforts critical for new entrants.

As oncology moves toward molecular subtyping and individualized treatment, demand is rising for therapies that offer high efficacy with minimal side effects. Therapeutic nuclear medicines are increasingly incorporated into treatment protocols for advanced-stage cancers. The integration of radiotherapy and diagnostics within hospital platforms is enhancing institutional acceptance and adoption. Meanwhile, global pharmaceutical leaders are accelerating the development of next-generation radiopharmaceuticals across multiple indications, driving broader clinical penetration and application scenarios.

This report presents a comprehensive overview of the global Therapeutic Nuclear Medicines market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Radium-223
• Lutetium-177
• Iodine-131
• Other

Segment by Application

• Thyroid
• Bone Metastasis
• Lymphoma
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Therapeutic Nuclear Medicines market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Thyroid, Bone Metastasis, Lymphoma evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact